• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy.

作者信息

Stemberkova-Hubackova Sona, Zobalova Renata, Dubisova Maria, Smigova Jana, Dvorakova Sarka, Korinkova Klara, Ezrova Zuzana, Endaya Berwini, Blazkova Kristyna, Vlcak Erik, Brisudova Petra, Le Dan-Diem Thi, Juhas Stefan, Rosel Daniel, Daniela Kelemen Cristina, Sovilj Dana, Vacurova Eliska, Cajka Tomas, Filimonenko Vlada, Dong Lanfeng, Andera Ladislav, Hozak Pavel, Brabek Jan, Bielcikova Zuzana, Stursa Jan, Werner Lukas, Neuzil Jiri

机构信息

Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic.

Faculty of Science, Charles University, Prague 1, Czech Republic.

出版信息

Clin Transl Med. 2022 Mar;12(3):e645. doi: 10.1002/ctm2.645.

DOI:10.1002/ctm2.645
PMID:35352502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8964933/
Abstract
摘要

相似文献

1
Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy.同时靶向线粒体代谢和免疫检查点作为肾癌治疗的新策略。
Clin Transl Med. 2022 Mar;12(3):e645. doi: 10.1002/ctm2.645.
2
[Imaging of Metastastic Renal Cell Carcinoma under Therapy with Immune Checkpoint Inhibitors].[免疫检查点抑制剂治疗下转移性肾细胞癌的影像学表现]
Rofo. 2017 Apr;189(4):287-292. doi: 10.1055/s-0043-100511. Epub 2017 Mar 23.
3
Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.转移性肾细胞癌的当前和新兴治疗靶点。
Curr Oncol Rep. 2018 Apr 2;20(5):41. doi: 10.1007/s11912-018-0684-z.
4
[Immunotherapy in kidney cancer: how it has changed and what are the challenges for the nephrologist - focus on pembrolizumab].
G Ital Nefrol. 2021 Oct 26;38(5):2021-vol5.
5
Checkpoint inhibitor immunotherapy in kidney cancer.检查点抑制剂免疫疗法在肾癌中的应用。
Nat Rev Urol. 2020 Mar;17(3):137-150. doi: 10.1038/s41585-020-0282-3. Epub 2020 Feb 4.
6
Targeting glyco-immune checkpoints for cancer therapy.针对糖基免疫检查点的癌症治疗。
Expert Opin Biol Ther. 2021 Aug;21(8):1063-1071. doi: 10.1080/14712598.2021.1882989. Epub 2021 Feb 8.
7
What advances have been made in immune-therapy for renal cell carcinoma?肾细胞癌免疫治疗取得了哪些进展？
Future Oncol. 2017 Apr;13(8):665-668. doi: 10.2217/fon-2017-0026. Epub 2017 Feb 10.
8
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.实体瘤免疫治疗患者选择：克服单一生物标志物的盲目观点。
Biomed Res Int. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019.
9
Immune therapy for kidney cancer: a second dawn?免疫疗法治疗肾癌：第二春？
Semin Oncol. 2013 Aug;40(4):492-8. doi: 10.1053/j.seminoncol.2013.05.008.
10
An unsuspected complication with immune checkpoint blockade: a case report.免疫检查点阻断的一种意外并发症：一例病例报告。
J Med Case Rep. 2018 Sep 4;12(1):246. doi: 10.1186/s13256-018-1782-0.

引用本文的文献

1
Role of ANT2 in mitochondrial function and cancer cell survival: a target for therapeutic intervention.ANT2在线粒体功能和癌细胞存活中的作用：一个治疗干预靶点。
Cell Death Discov. 2025 May 8;11(1):225. doi: 10.1038/s41420-025-02510-z.
2
Chelation of Mitochondrial Iron as an Antiparasitic Strategy.螯合线粒体铁作为一种抗寄生虫策略。
ACS Infect Dis. 2024 Feb 9;10(2):676-687. doi: 10.1021/acsinfecdis.3c00529. Epub 2024 Jan 30.
3
Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/Ib clinical trial.

本文引用的文献

1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer.程序性细胞死亡配体-1 介导的己糖激酶 2 表达增强与非小细胞肺癌 T 细胞效应基因表达呈负相关。
J Exp Clin Cancer Res. 2019 Nov 12;38(1):462. doi: 10.1186/s13046-019-1407-5.
3
线粒体靶向他莫昔芬作为抗癌疗法：I/Ib期临床试验中治疗的肾细胞癌患者病例系列
Ther Adv Med Oncol. 2023 Sep 30;15:17588359231197957. doi: 10.1177/17588359231197957. eCollection 2023.
4
MitoTam-01 Trial: Mitochondrial Targeting as Plausible Approach to Cancer Therapy. Comment on Yap et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. 2023, , 115-126.米托塔姆 - 01试验：线粒体靶向作为癌症治疗的可行方法。对亚普等人的评论。晚期实体瘤和急性髓系白血病中氧化磷酸化的复合体I抑制剂：I期试验。2023年，第115 - 126页。
Cancers (Basel). 2023 Sep 8;15(18):4476. doi: 10.3390/cancers15184476.
5
OXPHOS-targeting drugs in oncology: new perspectives.肿瘤治疗中的 OXPHOS 靶向药物：新视角。
Expert Opin Ther Targets. 2023 Jul-Dec;27(10):939-952. doi: 10.1080/14728222.2023.2261631. Epub 2023 Oct 30.
6
Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial.线粒体靶向他莫昔芬治疗转移性实体瘤患者：一项开放标签的I/Ib期单中心试验。
EClinicalMedicine. 2023 Feb 23;57:101873. doi: 10.1016/j.eclinm.2023.101873. eCollection 2023 Mar.
7
Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies.靶向衰老细胞“阴暗面”的新兴治疗方法：将衰老视为一种疾病并延缓与年龄相关疾病的新希望。
Cells. 2023 Mar 16;12(6):915. doi: 10.3390/cells12060915.
8
Effects of metabolic cancer therapy on tumor microenvironment.代谢性癌症疗法对肿瘤微环境的影响。
Front Oncol. 2022 Dec 13;12:1046630. doi: 10.3389/fonc.2022.1046630. eCollection 2022.
9
Repurposing of MitoTam: Novel Anti-Cancer Drug Candidate Exhibits Potent Activity against Major Protozoan and Fungal Pathogens.米托坦再利用：新型抗癌候选药物对主要原生动物和真菌病原体表现出强大的活性。
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0072722. doi: 10.1128/aac.00727-22. Epub 2022 Jul 20.
Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells.
二氢乳清酸脱氢酶驱动的嘧啶生物合成的再激活恢复了呼吸缺陷型癌细胞的肿瘤生长。
Cell Metab. 2019 Feb 5;29(2):399-416.e10. doi: 10.1016/j.cmet.2018.10.014. Epub 2018 Nov 15.
4
Selective Disruption of Respiratory Supercomplexes as a New Strategy to Suppress Her2 Breast Cancer.选择性破坏呼吸超复合物作为抑制Her2乳腺癌的新策略。
Antioxid Redox Signal. 2017 Jan 10;26(2):84-103. doi: 10.1089/ars.2016.6677. Epub 2016 Aug 22.
5
Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas.线粒体功能的治疗性抑制可诱导耐饥饿肾细胞癌发生细胞死亡。
Sci Rep. 2016 May 9;6:25669. doi: 10.1038/srep25669.
6
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.纳武单抗治疗转移性肾细胞癌：一项随机II期试验的结果
J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.
7
Classification of mitocans, anti-cancer drugs acting on mitochondria.米托坎分类，作用于线粒体的抗癌药物。
Mitochondrion. 2013 May;13(3):199-208. doi: 10.1016/j.mito.2012.07.112. Epub 2012 Jul 28.
8
Mitochondrial pharmacology.线粒体药理学。
Trends Pharmacol Sci. 2012 Jun;33(6):341-52. doi: 10.1016/j.tips.2012.03.010. Epub 2012 Apr 18.
9
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.多区域测序揭示的肿瘤内异质性和分支进化。
N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205.
10
Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells.离域亲脂性阳离子可选择性地靶向癌细胞的线粒体。
Adv Drug Deliv Rev. 2001 Jul 2;49(1-2):63-70. doi: 10.1016/s0169-409x(01)00125-9.